Random lopinavir
concentrations predict virologic failure in a cohort of South African children
R.R. Moholisa, M. Schomaker, L. Kuhn, et al
Poster
Abstract
POSTER
Predictors of renal
insufficiency in patients randomized to second-line lopinavir/ritonavir
monotherapy vs. tenofovir/lamivudine/lopinavir/ritonavir
J. Sophonphan, P. Chetchotisakd, W. Munsakul, et al
Poster
Abstract
POSTER
Rifabutin
pharmacokinetics when coadministered with lopinavir/ritonavir in HIV-infected
patients with tuberculosis in Viet Nam: results of ANRS12150b cross-over
clinical trial
N. Huy Dung, A. Barrail-Tran, N. Thi Ngoc Lan, et al
Poster
Abstract
A randomized study
comparing low dose versus standard dose lopinavir/ritonavir among HIV-infected
children with virological suppression
T. Put
Association of
SCLO1B1 polymorphism and plasma concentration of lopinavir in HIV-infected
children
P. Udomchaisakul, C. Srichomthong, N. Thammajaruk, et al
Microarray analysis
of subcutaneous adipose tissue from healthy HIV-seronegative adults exposed to
lopinavir/ritonavir exhibited significant changes in insulin signalling
R. Maughan, P. Doolan, S. Ahern, et al
Lopinavir and
atazanavir in pregnancy: comparable infant outcomes, virological efficacy and
preterm delivery rates
M. Perry, K. Conway, S. Flanagan, et al
Randomised
study to evaluate lopinavir/ritonavir vs. darunavir/ritonavir monotherapies as
simplification of triple therapy regimens
J.R. Santos, J. Moltó, J.M. Llibre, et al
Changes in bone
mineral density over 48 weeks among participants randomised to either
lopinavir/ritonavir (LPV/r) + 2-3N(t)RTI or LPV/r + raltegravir as second-line
therapy: a sub-study of the SECONDLINE trial
J. Hoy, A. Martin, C. Moore,et al
|
Documents identified with this icon are in
Portable Document Format (PDF) and require the
